Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) was up 1.8% during trading on Tuesday . The stock traded as high as $6.34 and last traded at $6.27, with a volume of 361,513 shares traded. The stock had previously closed at $6.16.

Several equities research analysts have commented on PGNX shares. Brean Capital set a $14.00 price target on Progenics Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 7th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Progenics Pharmaceuticals in a research note on Friday, July 22nd. Jefferies Group reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. Finally, BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Progenics Pharmaceuticals in a research note on Wednesday, July 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $9.95.

The stock’s 50 day moving average price is $6.39 and its 200-day moving average price is $5.25. The company’s market capitalization is $432.51 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/progenics-pharmaceuticals-inc-pgnx-trading-up-1-8.html

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its earnings results on Thursday, August 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.05. The business had revenue of $8.50 million for the quarter, compared to analysts’ expectations of $6.33 million. Progenics Pharmaceuticals had a negative return on equity of 41.76% and a negative net margin of 203.56%. The company’s quarterly revenue was up 337.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.17) EPS. Equities research analysts expect that Progenics Pharmaceuticals Inc. will post $0.13 EPS for the current year.

Several hedge funds have recently modified their holdings of PGNX. Schwab Charles Investment Management Inc. boosted its stake in shares of Progenics Pharmaceuticals by 111.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 217,100 shares of the company’s stock valued at $917,000 after buying an additional 114,500 shares during the period. KCG Holdings Inc. boosted its stake in shares of Progenics Pharmaceuticals by 71.0% in the second quarter. KCG Holdings Inc. now owns 43,712 shares of the company’s stock valued at $184,000 after buying an additional 18,142 shares during the period. ProShare Advisors LLC boosted its stake in shares of Progenics Pharmaceuticals by 0.6% in the second quarter. ProShare Advisors LLC now owns 60,586 shares of the company’s stock valued at $256,000 after buying an additional 387 shares during the period. Rhumbline Advisers boosted its stake in shares of Progenics Pharmaceuticals by 16.1% in the second quarter. Rhumbline Advisers now owns 80,988 shares of the company’s stock valued at $342,000 after buying an additional 11,223 shares during the period. Finally, Teachers Advisors Inc. boosted its stake in shares of Progenics Pharmaceuticals by 7.3% in the second quarter. Teachers Advisors Inc. now owns 109,166 shares of the company’s stock valued at $461,000 after buying an additional 7,442 shares during the period. 84.22% of the stock is owned by institutional investors and hedge funds.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

5 Day Chart for NASDAQ:PGNX

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.